TwitterLinkedInYoutubeSlideshareflickrIFPMA - Global Health Matters - BlogRSS
IFPMA Home

International Federation of Pharmaceutical Manufacturers & Associations



Filters
<< FirstLast >>

IFPMA Statement, WHO EB 136, Item 5.1, Framework of engagement with non-State actors

27 January 2015

IFPMA Statement, WHO EB 136, Item 9.3, Global Vaccine Action Plan

27 January 2015

IFPMA Statement in support of 2015 Gavi Replenishment

20 January 2015

Mr Masafumi Nogimori, Speach at the Closing Session: Representative Director, Chairman of the Board, Astellas Pharma Inc., and Vice President of the IFPMA

04 November 2014

Dr Stefan Oschmann, Inaugural speech – transcript: Member of the Executive Board and Chief Executive Officer Pharma, Merck KGaA, Darmstadt, Germany, and President of IFPMA

04 November 2014

Dr John C. Lechleiter, Farewell Remarks: Chairman, President, and Chief Executive Officer Eli Lilly and Company and IFPMA President

04 November 2014

United Nations NCD Review – Roundtable 2: “Fostering and strengthening national, regional and international partnerships and cooperation in support of efforts to address non-communicable diseases - NCDs”

11 July 2014

IFPMA Statement, WHA 67, Item 16.5, Combating antimicrobial resistance, including antibiotic resistance

24 May 2014

IFPMA Statement under WHA 67 agenda item 15.6 Regulatory system strengthening (resolution EB134.R19) Access to biotherapeutic products and ensuring quality, safety and efficacy

23 May 2014

IFPMA Statement under WHA 67, Check against delivery – Item 13.3 Prevention and Control of Non Communicable Diseases, NCD Global Coordination Mechanism

22 May 2014

IFPMA Statement under WHA 67 agenda item 11.3, Framework of engagement with non-State actors

20 May 2014

IFPMA Statement at mhGAP Forum, Geneva, October 7, 2013

10 October 2013

Filters
<< FirstLast >>
Filters
<< FirstLast >>

27 January 2015,

IFPMA Statement, WHO EB 136, Item 5.1, Framework of engagement with non-State actors

Details

27 January 2015,

IFPMA Statement, WHO EB 136, Item 9.3, Global Vaccine Action Plan

Details

20 January 2015,

IFPMA Statement in support of 2015 Gavi Replenishment

Details

04 November 2014,

Mr Masafumi Nogimori, Speach at the Closing Session: Representative Director, Chairman of the Board, Astellas Pharma Inc., and Vice President of the IFPMA

Details

04 November 2014,

Dr Stefan Oschmann, Inaugural speech – transcript: Member of the Executive Board and Chief Executive Officer Pharma, Merck KGaA, Darmstadt, Germany, and President of IFPMA

Category: Presidency, News

Details

04 November 2014,

Dr John C. Lechleiter, Farewell Remarks: Chairman, President, and Chief Executive Officer Eli Lilly and Company and IFPMA President

Category: News, Presidency

Details

11 July 2014,

United Nations NCD Review – Roundtable 2: “Fostering and strengthening national, regional and international partnerships and cooperation in support of efforts to address non-communicable diseases - NCDs”

Category: Statements

Details

24 May 2014,

IFPMA Statement, WHA 67, Item 16.5, Combating antimicrobial resistance, including antibiotic resistance

Category: Statements

Details

23 May 2014,

IFPMA Statement under WHA 67 agenda item 15.6 Regulatory system strengthening (resolution EB134.R19) Access to biotherapeutic products and ensuring quality, safety and efficacy

Category: Statements

Details

22 May 2014,

IFPMA Statement under WHA 67, Check against delivery – Item 13.3 Prevention and Control of Non Communicable Diseases, NCD Global Coordination Mechanism

Category: Statements

Details

20 May 2014,

IFPMA Statement under WHA 67 agenda item 11.3, Framework of engagement with non-State actors

Category: Statements

Details

10 October 2013,

IFPMA Statement at mhGAP Forum, Geneva, October 7, 2013

Details
Filters
<< FirstLast >>